-
1
-
-
0027416692
-
Effects of intermittent androgen suppression on androgen-dependent tumours: Apoptosis and serum prostale specific antigen
-
Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR and Sullivan LD (1993) Effects of intermittent androgen suppression on androgen-dependent tumours: apoptosis and serum prostale specific antigen. Cancer 71: 2782-2790
-
(1993)
Cancer
, vol.71
, pp. 2782-2790
-
-
Akakura, K.1
Bruchovsky, N.2
Goldenberg, S.L.3
Rennie, P.S.4
Buckley, A.R.5
Sullivan, L.D.6
-
2
-
-
0002499085
-
On the nature and clinical use of tissue polypeptide antigen (TPA)
-
Bjorklund B (1980) On the nature and clinical use of tissue polypeptide antigen (TPA). Tumour Diagnostik 1: 9-20
-
(1980)
Tumour Diagnostik
, vol.1
, pp. 9-20
-
-
Bjorklund, B.1
-
3
-
-
0028061547
-
From tissue polypeptide antigen to specific cytokeratin assays
-
Börmer OP (1994) From tissue polypeptide antigen to specific cytokeratin assays. Tumor Biol 9: 185-187
-
(1994)
Tumor Biol
, vol.9
, pp. 185-187
-
-
Börmer, O.P.1
-
4
-
-
0025246690
-
Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma
-
Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M and Lawson D (1990) Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 50: 2275-2282
-
(1990)
Cancer Res
, vol.50
, pp. 2275-2282
-
-
Bruchovsky, N.1
Rennie, P.S.2
Coldman, A.J.3
Goldenberg, S.L.4
To, M.5
Lawson, D.6
-
5
-
-
0029050259
-
Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma
-
Bruchovsky N, Goldenberg SL, Rennie PS and Gleave M (1995) Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma. Urologe-A 34: 389-392
-
(1995)
Urologe-A
, vol.34
, pp. 389-392
-
-
Bruchovsky, N.1
Goldenberg, S.L.2
Rennie, P.S.3
Gleave, M.4
-
6
-
-
0028804123
-
Commentary on maximal androgen blockade in prostate cancer: A theory to put into practise?
-
Denis L (1995) Commentary on maximal androgen blockade in prostate cancer: a theory to put into practise? Prostate 27: 233-240
-
(1995)
Prostate
, vol.27
, pp. 233-240
-
-
Denis, L.1
-
7
-
-
0028817056
-
Tissue polypeptide-speeific antigen (TPS) in monitoring palliative treatment response of patients with gastrointestinal tumours
-
Kornek G, Schenk T, Raderer M, Djavarnmad M and Scheithauer W (1995) Tissue polypeptide-speeific antigen (TPS) in monitoring palliative treatment response of patients with gastrointestinal tumours. Br J Cancer 71: 182-185
-
(1995)
Br J Cancer
, vol.71
, pp. 182-185
-
-
Kornek, G.1
Schenk, T.2
Raderer, M.3
Djavarnmad, M.4
Scheithauer, W.5
-
8
-
-
0000035768
-
Carcinoma of the prostate
-
Gillenwater JY, Grayhack JP, Howards SS and Duckett JW (eds), Yearbook Medical: Chicago
-
Kozlowski JM and Grayhack JP (1996) Carcinoma of the prostate. In Adult and Pediatric Urology. 3rd edn, Gillenwater JY, Grayhack JP, Howards SS and Duckett JW (eds), pp. 1679- 1689. Yearbook Medical: Chicago
-
(1996)
Adult and Pediatric Urology. 3rd Edn
, pp. 1679-1689
-
-
Kozlowski, J.M.1
Grayhack, J.P.2
-
9
-
-
0025915563
-
Prostate specific antigen in hormonally treated D2 prostate cancer; is it always an accurate indicator of disease status?
-
Leo ME, Bilhartz DL, Bergstrahl EJ and Oesterling JE (1991) Prostate specific antigen in hormonally treated D2 prostate cancer; is it always an accurate indicator of disease status? J Urol 145: 802-807
-
(1991)
J Urol
, vol.145
, pp. 802-807
-
-
Leo, M.E.1
Bilhartz, D.L.2
Bergstrahl, E.J.3
Oesterling, J.E.4
-
10
-
-
0026608176
-
Tissue polypeptide specific antigen (TPS) and objective response to treatment in solid tumours
-
Marino P, Buccheri G, Preatoni A, Ferrigno D, Luporini AC and Pravettoni G (1992) Tissue polypeptide specific antigen (TPS) and objective response to treatment in solid tumours. Int J Biol Markers 7: 65-67
-
(1992)
Int J Biol Markers
, vol.7
, pp. 65-67
-
-
Marino, P.1
Buccheri, G.2
Preatoni, A.3
Ferrigno, D.4
Luporini, A.C.5
Pravettoni, G.6
-
11
-
-
0027473197
-
Tissue polypeptide-specific antigen: A discriminative parameter between prostate cancer and benign prostatic hypertrophy
-
Marrink J, Oosterom R, Bonfrer HMG, Schröder FH, Mensink HJA (1993) Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy. Eur J Cancer 29A: 570-571
-
(1993)
Eur J Cancer
, vol.29 A
, pp. 570-571
-
-
Marrink, J.1
Oosterom, R.2
Bonfrer, H.M.G.3
Schröder, F.H.4
Mensink, H.J.A.5
-
12
-
-
0026525245
-
The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer
-
Miller JL, Ahmann FR, Drach GW, Emerson SS and Bottacini MR (1992) The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 147: 956-961
-
(1992)
J Urol
, vol.147
, pp. 956-961
-
-
Miller, J.L.1
Ahmann, F.R.2
Drach, G.W.3
Emerson, S.S.4
Bottacini, M.R.5
-
13
-
-
0025869392
-
Prostate specific antigen. A critical assessment of the most useful tumour marker tor adenocarcinoma of the prostate
-
Oesterling JE (1991) Prostate specific antigen. A critical assessment of the most useful tumour marker tor adenocarcinoma of the prostate. J Urol 145: 907-923
-
(1991)
J Urol
, vol.145
, pp. 907-923
-
-
Oesterling, J.E.1
-
14
-
-
0029005162
-
Clinical evaluation of seven tumour markers in lung cancer diagnosis: Can any combination improve the results?
-
Plebani M, Basso D, Navaglia F, De-Paoli M, Tommasini A and Cipriani A (1995) Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results? Br J Cancer 72: 170-173
-
(1995)
Br J Cancer
, vol.72
, pp. 170-173
-
-
Plebani, M.1
Basso, D.2
Navaglia, F.3
De-Paoli, M.4
Tommasini, A.5
Cipriani, A.6
-
15
-
-
0027209937
-
Serial measurements of tissue polypeptide specific antigen (TPS). PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer
-
Tarle M (1993) Serial measurements of tissue polypeptide specific antigen (TPS). PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer. Anticancer Res 13: 769-778
-
(1993)
Anticancer Res
, vol.13
, pp. 769-778
-
-
Tarle, M.1
-
16
-
-
0027479716
-
Correlation of cell proliferation marker (TPS), Natural Killer (NK) activity and tumour load serotest (PSA) in untreated and treated prostatic tumours
-
Tarle M, Kovacic K and Kastelan M (1993) Correlation of cell proliferation marker (TPS), Natural Killer (NK) activity and tumour load serotest (PSA) in untreated and treated prostatic tumours. Anticancer Res 13: 215-218
-
(1993)
Anticancer Res
, vol.13
, pp. 215-218
-
-
Tarle, M.1
Kovacic, K.2
Kastelan, M.3
-
17
-
-
0028302956
-
A more objective staging of advanced prostate cancer routine recognition of malignant endocrine structures: The assessment of serum TPS, PSA and NSE values
-
Tarle M, Erkovic-Grazio S, Kraljic I and Kovacic K (1994) A more objective staging of advanced prostate cancer routine recognition of malignant endocrine structures: the assessment of serum TPS, PSA and NSE values. Prostate 24: 143-148
-
(1994)
Prostate
, vol.24
, pp. 143-148
-
-
Tarle, M.1
Erkovic-Grazio, S.2
Kraljic, I.3
Kovacic, K.4
-
18
-
-
0028599490
-
Role of multidrug resistance in tumours of the genitourinary tract
-
Theyer G and Hamilton G (1994) Role of multidrug resistance in tumours of the genitourinary tract. Urology 44: 942-950
-
(1994)
Urology
, vol.44
, pp. 942-950
-
-
Theyer, G.1
Hamilton, G.2
-
19
-
-
0027532535
-
Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer
-
Yagoda A and Petralyk D (1993) Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71: 1098-1109
-
(1993)
Cancer
, vol.71
, pp. 1098-1109
-
-
Yagoda, A.1
Petralyk, D.2
|